MX2019003984A - Formulaciones de enzalutamida. - Google Patents

Formulaciones de enzalutamida.

Info

Publication number
MX2019003984A
MX2019003984A MX2019003984A MX2019003984A MX2019003984A MX 2019003984 A MX2019003984 A MX 2019003984A MX 2019003984 A MX2019003984 A MX 2019003984A MX 2019003984 A MX2019003984 A MX 2019003984A MX 2019003984 A MX2019003984 A MX 2019003984A
Authority
MX
Mexico
Prior art keywords
enzalutamide
formulations
disclosure provides
hyperproliferative disorders
provides formulations
Prior art date
Application number
MX2019003984A
Other languages
English (en)
Inventor
Alan Lorenz Douglas
Konagurthu Sanjay
J Wald Randy
A Everett Jason
Matz Sheila
Takaishi Yuuki
Sakai Toshiro
Irie Ryousuke
Oba Shinsuke
Toyota Hyroyasu
Nishimura Koji
Kanbayashi Atsushi
Original Assignee
Medivation Prostate Therapeutics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49231627&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX2019003984(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Medivation Prostate Therapeutics Llc filed Critical Medivation Prostate Therapeutics Llc
Publication of MX2019003984A publication Critical patent/MX2019003984A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
    • A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2095—Tabletting processes; Dosage units made by direct compression of powders or specially processed granules, by eliminating solvents, by melt-extrusion, by injection molding, by 3D printing
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/86—Oxygen and sulfur atoms, e.g. thiohydantoin

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Pregnancy & Childbirth (AREA)
  • Gynecology & Obstetrics (AREA)
  • Dispersion Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La descripción proporciona las formulaciones de enzalutamida y su uso para el tratamiento de trastornos hiperfroliferativos.
MX2019003984A 2012-09-11 2015-03-11 Formulaciones de enzalutamida. MX2019003984A (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261699351P 2012-09-11 2012-09-11

Publications (1)

Publication Number Publication Date
MX2019003984A true MX2019003984A (es) 2019-08-12

Family

ID=49231627

Family Applications (3)

Application Number Title Priority Date Filing Date
MX2015003140A MX363974B (es) 2012-09-11 2013-09-11 Formulaciones de enzalutamida.
MX2021000007A MX2021000007A (es) 2012-09-11 2015-03-11 Formulaciones de enzalutamida.
MX2019003984A MX2019003984A (es) 2012-09-11 2015-03-11 Formulaciones de enzalutamida.

Family Applications Before (2)

Application Number Title Priority Date Filing Date
MX2015003140A MX363974B (es) 2012-09-11 2013-09-11 Formulaciones de enzalutamida.
MX2021000007A MX2021000007A (es) 2012-09-11 2015-03-11 Formulaciones de enzalutamida.

Country Status (28)

Country Link
US (9) US20140179749A1 (es)
EP (5) EP4324527A3 (es)
JP (5) JP6404217B2 (es)
KR (1) KR102225416B1 (es)
CN (2) CN105358535B (es)
AU (2) AU2013315619B2 (es)
BR (1) BR112015005432B1 (es)
CA (1) CA2884795C (es)
CY (1) CY1124729T1 (es)
DK (1) DK3725778T3 (es)
EA (2) EA201991484A1 (es)
ES (1) ES2892029T3 (es)
HK (1) HK1212701A1 (es)
HR (1) HRP20211423T1 (es)
HU (1) HUE057701T2 (es)
IL (1) IL237604B (es)
IN (1) IN2015DN02875A (es)
LT (1) LT3725778T (es)
MX (3) MX363974B (es)
PH (1) PH12015500525A1 (es)
PL (1) PL3725778T3 (es)
PT (1) PT3725778T (es)
RS (1) RS62676B1 (es)
SI (1) SI3725778T1 (es)
TW (1) TWI673051B (es)
UA (1) UA117353C2 (es)
WO (1) WO2014043208A1 (es)
ZA (1) ZA201501847B (es)

Families Citing this family (58)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE057701T2 (hu) 2012-09-11 2022-05-28 Medivation Prostate Therapeutics Llc Enzalutamid kiszerelési formái
ES2836424T3 (es) 2012-09-26 2021-06-25 Aragon Pharmaceuticals Inc Antiandrógenos para tratar el cáncer de próstata no metastásico y resistente a la castración
UA115805C2 (uk) 2013-04-17 2017-12-26 Сігнал Фармасьютікалз, Елелсі Комбінована терапія, яка включає сполуку дигідропіразинопіразину й антагоніст рецептора андрогену, для лікування раку простати
KR20200015830A (ko) * 2014-02-05 2020-02-12 레크 파마슈티칼스 디.디. 안드로겐 수용체 길항제의 고체 제약 조성물
CN104356068A (zh) * 2014-10-30 2015-02-18 杭州新博思生物医药有限公司 恩杂鲁胺新晶型及其制备方法
EA035988B1 (ru) * 2014-12-05 2020-09-09 Арагон Фармасьютикалз, Инк. Противораковые композиции
CN106999432A (zh) 2014-12-05 2017-08-01 阿拉贡药品公司 抗癌组合物
MA41107A (fr) * 2014-12-05 2017-10-10 Aragon Pharmaceuticals Inc Compositions anti-cancéreuses
CN104546714A (zh) * 2015-02-11 2015-04-29 江苏慧博生物科技有限公司 一种恩杂鲁胺胶束制剂及其制备方法
CA2976360A1 (en) * 2015-02-11 2016-08-18 Aptevo Research And Development Llc Compositions and methods for combination therapy with prostate-specific membrane antigen binding proteins
CN104857517B (zh) * 2015-05-14 2018-04-27 南京海纳医药科技股份有限公司 一种恩杂鲁胺软胶囊及其制备方法
CN105030685B (zh) * 2015-07-21 2018-02-27 福格森（武汉）生物科技股份有限公司 一种恩杂鲁胺固体分散体口服制剂
WO2017027665A1 (en) 2015-08-12 2017-02-16 Medivation Prostate Therapeutics, Inc. Treatment of cancer using a combination of enzalutamide and a cyp3a4 inducer
WO2017035263A1 (en) * 2015-08-24 2017-03-02 Biocryst Pharmaceuticals, Inc. Compositions comprising a plasma kallikrein inhibitor
KR20180053322A (ko) 2015-09-21 2018-05-21 압테보 리서치 앤드 디벨롭먼트 엘엘씨 Cd3 결합 폴리펩타이드
EP3355865A1 (en) 2015-09-29 2018-08-08 Acorda Therapeutics, Inc. Sustained release compositions of 4-aminopyridine
CN107126419B (zh) * 2016-02-26 2020-06-19 石药集团中诺药业（石家庄）有限公司 一种奥贝胆酸片剂及其制备方法
ES2900149T3 (es) 2016-07-21 2022-03-16 Hadasit Med Res Service Combinaciones que comprenden antagonistas o inhibidores de AR para su uso en el tratamiento del glioblastoma
CA3036011A1 (en) 2016-08-20 2018-03-01 Ftf Pharma Private Limited Pharmaceutical composition comprising an androgen receptor inhibitor
AU2018252153A1 (en) * 2017-04-13 2019-11-07 Jean Paul Remon Xanthohumol-based compositions
CN110573153B (zh) * 2017-04-28 2023-04-04 安斯泰来制药有限公司 含有恩杂鲁胺的口服给药用药物组合物
EP3641772B1 (en) 2017-06-22 2023-08-02 Celgene Corporation Treatment of hepatocellular carcinoma characterized by hepatitis b virus infection
WO2019016747A1 (en) * 2017-07-20 2019-01-24 Dr. Reddy's Laboratories Limited AMORPHOUS SOLID DISPERSIONS OF APALUTAMIDE AND PROCESS FOR THEIR PREPARATION
WO2019030691A1 (en) * 2017-08-08 2019-02-14 Dr. Reddy’S Laboratories Limited EXTRUDED COMPOSITIONS OF ENZALUTAMIDE
KR20200070334A (ko) 2017-10-16 2020-06-17 아라곤 파마슈티컬스, 인코포레이티드 비-전이성 거세-저항성 전립선암의 치료를 위한 항-안드로겐
WO2019155416A2 (en) * 2018-02-09 2019-08-15 Kashiv Pharma Llc A stable pharmaceutical composition of poorly soluble nonsteroidal antiandrogens
EP3773509B1 (en) 2018-04-06 2023-11-01 Capsugel Belgium NV Spray drying process for low aspect ratio particles comprising poly[(methyl methacrylate)-co-(methacrylic acid)]
CZ2018234A3 (cs) 2018-05-21 2019-12-04 Zentiva Ks Zvýšení rozpustnosti a biodostupnosti enzalutamidu
EA202191372A1 (ru) * 2018-12-14 2021-09-16 Фуджифилм Корпорэйшн Таблетка и способ получения таблетки
CN109432016B (zh) * 2018-12-26 2021-03-02 广州中医药大学(广州中医药研究院) 一种恩杂鲁胺的三元固体制剂及其制备方法
WO2020144647A1 (en) 2019-01-10 2020-07-16 Aragon Pharmaceuticals, Inc. Pharmaceutical composition comprising apalutamide dispersed in apple sauce
SG11202107712SA (en) 2019-01-30 2021-08-30 Aragon Pharmaceuticals Inc Anti-androgens for the treatment of metastatic castration-sensitive prostate cancer
KR20210122275A (ko) 2019-01-30 2021-10-08 얀센 파마슈티카 엔.브이. 분자 아형에 기초하여 전립선암을 치료하는 방법
WO2020229702A1 (en) 2019-05-16 2020-11-19 Leon-Nanodrugs Gmbh Method for producing nanoparticles
WO2020234448A1 (en) 2019-05-23 2020-11-26 Helm Ag Nanoparticles comprising enzalutamide
WO2020239478A1 (en) 2019-05-28 2020-12-03 Pharma Mar, S.A. Trabectedin for treating sarcomas based on genomic markers
CA3143111A1 (en) 2019-06-27 2020-12-30 Synthon B.V. Process for preparation of enzalutamide
CN114727949A (zh) * 2019-09-18 2022-07-08 百时美施贵宝公司 Tyk2抑制剂的剂型
EP4034113A4 (en) * 2019-09-23 2023-08-23 Bionomics Limited THERAPEUTIC FORMULATIONS AND THEIR USES
EP4037659A1 (en) 2019-10-03 2022-08-10 Synthon BV Pharmaceutical composition comprising enzalutamide
EP4054572A1 (en) 2019-11-04 2022-09-14 Aragon Pharmaceuticals, Inc. Androgen receptor inhibitors for the treatment of non-metastatic castration-resistant prostate cancer in subjects with severe hepatic impairment
AR118925A1 (es) * 2020-05-13 2021-11-10 Novocap S A Solución líquida concentrada de antiandrógenos no esteroideos y procedimiento para preparar la solución
WO2021240206A1 (en) 2020-05-24 2021-12-02 Lotus International Pte. Ltd. Enzalutamide formulation
WO2021245285A1 (en) 2020-06-05 2021-12-09 Janssen Pharmaceutica Nv Methods of treating prostate cancer based on molecular subtypes
CN114053243A (zh) * 2020-08-05 2022-02-18 齐鲁制药有限公司 一种恩扎卢胺软胶囊及其制备方法
WO2022049523A1 (en) 2020-09-04 2022-03-10 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
WO2022195407A1 (en) 2021-03-19 2022-09-22 Aragon Pharmaceuticals, Inc. Methods for treating prostate cancer
CN115721612B (zh) * 2021-08-26 2024-07-26 上海宣泰医药科技股份有限公司 一种恩扎卢胺固体制剂颗粒及其制备方法
WO2023138366A1 (zh) * 2022-01-19 2023-07-27 四川科伦药物研究院有限公司 固体分散体及其制备方法和包含其的药物组合物
CN114224832A (zh) * 2022-02-11 2022-03-25 明度智云(浙江)科技有限公司 一种恩杂鲁胺注射剂及其制备方法和应用
WO2023152611A1 (en) 2022-02-11 2023-08-17 Aragon Pharmaceuticals, Inc. Apalutamide and relugolix for the treatment of prostate cancer
WO2023209555A1 (en) 2022-04-26 2023-11-02 Aragon Pharmaceuticals, Inc. Approved drug products and methods for treating prostate cancer
WO2023244617A1 (en) * 2022-06-13 2023-12-21 Virginia Polytechnic Institute And State University Amphiphilic cellulose derivatives, methods of making, and uses thereof
TW202416960A (zh) * 2022-06-17 2024-05-01 美商特朗奎斯治療股份有限公司 2-芳基苯并咪唑化合物之調配物
CN115887395A (zh) * 2022-11-18 2023-04-04 上海药坦药物研究开发有限公司 恩杂鲁胺固体分散体制剂及其制备方法和应用
EP4374853A1 (en) 2022-11-22 2024-05-29 Lotus Pharmaceutical Co., Ltd. Solid formulation of enzalutamide
WO2024153733A1 (en) 2023-01-18 2024-07-25 Helm Ag Crystalline nanoparticles comprising enzalutamide
CN118001243A (zh) * 2024-01-31 2024-05-10 四川鲁徽制药有限责任公司 一种恩杂鲁胺口腔崩解片及其制备方法

Family Cites Families (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5656651A (en) * 1995-06-16 1997-08-12 Biophysica Inc. Androgenic directed compositions
TW486370B (en) 1996-12-25 2002-05-11 Yamanouchi Pharma Co Ltd Rapidly disintegrable pharmaceutical composition
DK0901786T3 (da) 1997-08-11 2007-10-08 Pfizer Prod Inc Faste farmaceutiske dispersioner med foröget biotilgængelighed
EP1745774A3 (en) 1997-08-11 2007-04-11 Pfizer Products Inc. Solid pharmaceutical dispersions with enhanced bioavailability
IN191496B (es) * 1999-07-30 2003-12-06 Ranbaxy Lab Ltd
AR027656A1 (es) 2000-03-16 2003-04-09 Pfizer Prod Inc Composiciones farmaceuticas de inhibidores de la glucogeno-fosforilasa
RU2003128971A (ru) 2001-02-27 2005-03-10 Астразенека Аб (Se) Фармацевтический препарат
SE0103424D0 (sv) 2001-10-15 2001-10-15 Astrazeneca Ab Pharmaceutical formulation
GB2383042A (en) * 2001-10-18 2003-06-18 Cipla Ltd Amorphous alendronate sodium
SE0103839D0 (sv) 2001-11-16 2001-11-16 Astrazeneca Ab Pharmaceutical formulation & product
KR100758045B1 (ko) * 2002-02-01 2007-09-11 화이자 프로덕츠 인크. 압력 노즐을 이용하여 균질한 분무 건조된 비결정질 고체약물 분산제를 제조하는 방법
JP2005523360A (ja) * 2002-04-18 2005-08-04 アベシア・リミテッド 共役分子の製造および製造において使用するための物質
JP4249950B2 (ja) 2002-06-28 2009-04-08 富士フイルム株式会社 紙管切断装置及び紙管切断方法
US20050020675A1 (en) 2003-02-21 2005-01-27 Parthasaradhi Reddy Bandi Bicalutamide polymorphs
EP1730516A1 (en) 2004-03-30 2006-12-13 Pfizer Products Incorporated Method and device for evaluation of pharmaceutical compositions
PT2444085E (pt) * 2005-05-13 2015-06-11 Univ California Compostos de diaril-hidantoínas como antagonistas do recetor androgénio para tratamento de cancro
US7709517B2 (en) * 2005-05-13 2010-05-04 The Regents Of The University Of California Diarylhydantoin compounds
CA2608952A1 (en) * 2005-05-19 2006-11-23 Dwayne Thomas Friesen Pharmaceutical compostions comprising an amorphous form of a vegf-r inhibitor
CN101272848B (zh) 2005-07-28 2013-03-13 Isp投资有限公司 改进喷雾干燥的粉末和颗粒材料性质的方法，以及由此生产的产品
PL2656841T3 (pl) 2006-03-27 2017-01-31 The Regents Of The University Of California Modulator receptora androgenowego do leczenia raka gruczołu krokowego i chorób związanych z receptorem androgenowym
WO2008080037A2 (en) 2006-12-21 2008-07-03 Isp Investments Inc. Carotenoids of enhanced bioavailability
US20100151035A1 (en) 2007-03-13 2010-06-17 Sandoz Ag Pharmaceutical compositions of poorly soluble drugs
JP5437232B2 (ja) 2008-03-11 2014-03-12 あすか製薬株式会社 固体分散体とその医薬組成物、並びにそれらの製造方法
US9447089B2 (en) 2009-04-03 2016-09-20 Plexxikon Inc. Compositions and uses thereof
US20100297194A1 (en) * 2009-04-30 2010-11-25 Nathaniel Catron Formulation for oral administration of apoptosis promoter
PL2538785T3 (pl) * 2010-02-24 2018-08-31 Medivation Prostate Therapeutics Llc Sposoby syntezy zwiazków diarylotiohydantoinowych i diarylohydantoinowych
ES2613608T3 (es) * 2010-03-10 2017-05-24 Abbvie Ireland Unlimited Company Composiciones sólidas
ES2670683T3 (es) 2012-06-07 2018-05-31 Aragon Pharmaceuticals, Inc. Formas cristalinas de un modulador de receptor de andrógenos
US9515365B2 (en) * 2012-08-10 2016-12-06 Keyssa, Inc. Dielectric coupling systems for EHF communications
CA2884640A1 (en) 2012-09-11 2014-03-20 Dr. Reddy's Laboratories Limited Enzalutamide polymorphic forms and its preparation
HUE057701T2 (hu) 2012-09-11 2022-05-28 Medivation Prostate Therapeutics Llc Enzalutamid kiszerelési formái
US9713594B2 (en) 2012-09-11 2017-07-25 Bend Research, Inc. Methods for making pharmaceutical solid dosage forms of spray-dried dispersions
WO2014167428A2 (en) 2013-04-10 2014-10-16 Shilpa Medicare Limited Amorphous 4-(3-(4-cyano-3-(trifluoromethyl)phenyl)-5,5-dimethyl-4-oxo-2-thioxoimidazolidin-1-yl)-2-fluoro-n-methylbenzamide
CN110573153B (zh) 2017-04-28 2023-04-04 安斯泰来制药有限公司 含有恩杂鲁胺的口服给药用药物组合物
US20190208236A1 (en) 2018-01-02 2019-07-04 Source Digital, Inc. Coordinates as ancillary data
EP4037659A1 (en) 2019-10-03 2022-08-10 Synthon BV Pharmaceutical composition comprising enzalutamide

Also Published As

Publication number Publication date
BR112015005432B1 (pt) 2023-04-18
EP4324527A2 (en) 2024-02-21
SI3725778T1 (sl) 2022-02-28
HRP20211423T1 (hr) 2022-01-21
MX363974B (es) 2019-04-10
EP4324527A3 (en) 2024-04-24
CN105358535A (zh) 2016-02-24
DK3725778T3 (da) 2021-09-20
UA117353C2 (uk) 2018-07-25
US20170027910A1 (en) 2017-02-02
JP6404217B2 (ja) 2018-10-10
JP2019194262A (ja) 2019-11-07
ZA201501847B (en) 2016-01-27
JP2015527411A (ja) 2015-09-17
CA2884795A1 (en) 2014-03-20
HK1212701A1 (zh) 2016-06-17
US11839689B2 (en) 2023-12-12
JP2021178871A (ja) 2021-11-18
IL237604B (en) 2021-07-29
AU2013315619B2 (en) 2018-02-08
TW201427659A (zh) 2014-07-16
EP3725778A1 (en) 2020-10-21
JP2016204392A (ja) 2016-12-08
US20140378517A1 (en) 2014-12-25
HUE057701T2 (hu) 2022-05-28
EA201500314A1 (ru) 2015-12-30
EA201991484A1 (ru) 2019-11-29
EA033374B1 (ru) 2019-10-31
US20190209476A1 (en) 2019-07-11
PL3725778T3 (pl) 2021-12-20
US20230122911A1 (en) 2023-04-20
US20140179749A1 (en) 2014-06-26
RS62676B1 (sr) 2021-12-31
EP3971167A1 (en) 2022-03-23
MX2015003140A (es) 2015-12-16
PH12015500525A1 (en) 2015-05-04
LT3725778T (lt) 2021-12-27
TWI673051B (zh) 2019-10-01
US20200060976A1 (en) 2020-02-27
AU2013315619A1 (en) 2015-04-30
US20230210778A1 (en) 2023-07-06
BR112015005432A2 (es) 2017-09-05
ES2892029T3 (es) 2022-02-01
EP2895463A1 (en) 2015-07-22
KR102225416B1 (ko) 2021-03-09
CN105358535B (zh) 2019-01-04
US20170224624A1 (en) 2017-08-10
CA2884795C (en) 2023-10-17
JP6932746B2 (ja) 2021-09-08
CN109897004A (zh) 2019-06-18
JP2018087206A (ja) 2018-06-07
CY1124729T1 (el) 2022-07-22
IN2015DN02875A (es) 2015-09-11
KR20150082203A (ko) 2015-07-15
EA033374B9 (ru) 2019-12-18
IL237604A0 (en) 2015-04-30
MX2021000007A (es) 2021-03-09
AU2018200316A1 (en) 2018-02-08
EP3725778B1 (en) 2021-08-18
EP4169908A1 (en) 2023-04-26
PT3725778T (pt) 2021-09-22
US20140100256A1 (en) 2014-04-10
WO2014043208A1 (en) 2014-03-20

Similar Documents

Publication Publication Date Title
PH12015500525A1 (en) Formulations of enzalutamide
IL239355A0 (en) Compositions of gamma-hydroxybutyrate and their use in the treatment of disorders
HK1217289A1 (zh) 使用細菌治療癌症的組合物和方法
PH12014502132A1 (en) Anti-lgr5 antibodies and immunoconjugates
IN2015DN00127A (es)
MY168032A (en) Warm-Cool Beauty Treatment Device
PH12014501605A1 (en) Anti-lrp5 antibodies and methods of use
IN2014DN11201A (es)
IL238177A0 (en) Methods and preparations for the treatment of cancer
EP2897689A4 (en) COMPOSITIONS AND METHODS OF TREATING ALOPEZIA
ZA201408055B (en) Compositions and methods for the treatment of local pain
IL239374A0 (en) Preparations and methods for treating brain tumors
MX2016008150A (es) Formulaciones de berberina y usos de las mismas.
GEP201706764B (en) Quinazolin-thf-amines as pde1 inhibitors
ZA201408060B (en) Compositions and methods for the treatment of neurological disorders
GEP20186920B (en) Halogenated quinazolinthf-amines as pde1 inhibitors
EA201590615A1 (ru) Стимулирующие лактацию композиции на основе фосфатидилсерина
EP2800568A4 (en) COMPOSITIONS, USE METHOD AND TREATMENT METHOD THEREFOR
ZA201408061B (en) Compositions and methods for the treatment of neurological disorders
EP2825184A4 (en) COMPOSITIONS AND METHODS FOR THE TREATMENT OF PAIN
MY168958A (en) Intermediates and processes for preparing compounds
AU2013902004A0 (en) Compositions for Therapy and Methods of Treatment
UA80618U (en) Use of n-steroylethanolamine as radiomodifier
AU2012902296A0 (en) Compositions for Therapy and Methods of Treatment